The Intersection of Alcohol Dependence and Major Depressive Disorder: Genetic, Psychological, and Treatment Implications

Mohammed Thamr Almutairi [1*], Raed Mohammed Alomair [1], Abdulrahman Awadh H Alharbi [1], Mohammed Salem Alshammari [1], Sultan Safah A Alharbi [1], Abdullah Marzouq Alotaibai [1], Khalid Obid Abdullah Alruki [1], Mohammed Menwer Alruwaili [1], Saleh Helayyil Saleh Alharbi [1], Taleb Ghazi Thaar Aldalbahi [1], Hatim Bunaydir Bader AImutairi [1], Amer Hassan Mohammed Al-Shahri [1], Hassan Duairam Thawab Al-Shahrani [1], Hassan Duairam Thawab Al-Shahrani [1]

Abstract

Background: The comorbidity of major depressive disorder (MDD) and alcohol use disorder (AUD) represents a significant public health challenge, influencing treatment outcomes and recovery. Both conditions often share overlapping neurobiological mechanisms, complicating clinical management and prognosis. Polygenic scores, serotoninergic dysfunction, and neural plasticity changes are pivotal in understanding this dual pathology. Methods: A comprehensive review of studies examining the relationship between MDD and AUD was conducted, focusing on genetic, neurobiological, and therapeutic interventions. Data were sourced from randomized controlled trials, meta-analyses, and genetic studies, evaluating pharmacological treatments, psychotherapy, and integrative approaches. Key interventions included antidepressants, naltrexone, and cognitive-behavioral therapy (CBT). Results: Genetic studies indicate a shared genetic susceptibility between MDD and AUD, with polygenic risk scores showing a strong correlation. Pharmacological treatments, such as selective serotonin reuptake inhibitors (SSRIs) and the combination of antidepressants with alcohol-sensitizing agents (e.g., naltrexone), demonstrated significant efficacy in managing both disorders concurrently. Psychotherapeutic interventions, particularly CBT and motivational interviewing, were effective in reducing substance use and depressive symptoms, with integrative approaches providing the best outcomes. Conclusion: The comorbidity of MDD and AUD is multifactorial, with both genetic and neurobiological factors playing a crucial role. Integrated treatment strategies, combining pharmacological and psychological interventions, are essential for addressing the complex needs of patients. Ongoing research into the shared pathophysiological mechanisms and personalized treatment approaches holds promise for improving long-term recovery outcomes in individuals with these dual diagnoses.

Keywords: Alcohol Dependence, Major Depression, Genetic Predisposition, Treatment Efficacy, Comorbid Disorders

Significance | This review discusses the genetic and psychological underpinnings of alcohol dependence and major depression, highlighting treatment strategies and implications.

*Correspondence. Mohammed Thamr Almutairi, Ministry of National Guard Health Affairs, Prince Mutib Ibn Abdullah Ibn Abdulaziz Rd, Ar Rimayah, Riyadh 11426, Saudi Arabia
E-mail: akrmesmail2060@gmail.com

Editor Md Shamsuddin sultan khan And accepted by the Editorial Board January 05, 2020 (received for review November 01, 2019)

1. Introduction

Comorbidity of Alcohol Use Disorder and Depressive Disorders Psychiatric disorders and substance use disorders (SUDs) frequently co-occur, posing substantial challenges to clinical management and research. Among these co-occurring conditions,

Author Affiliation.
[1] Ministry of National Guard Health Affairs, Prince Mutib Ibn Abdullah Ibn Abdulaziz Rd, Ar Rimayah, Riyadh 11426, Saudi Arabia.

Please Cite This:
Almutairi, M. T., alomair, &. M., Alharbi, &. A. H., Alshammari, M. S., Alharbi, S. S. A., Alotaibai, A. M., Alruki, K. O. A., Alruwaili, M. M., Alharbi, S. H. S., Aldalbahi, T. G. T., Almutairi, H. B. B. (2020). "The Intersection of Alcohol Dependence and Major Depressive Disorder: Genetic, Psychological, and Treatment Implications", Journal of Angiotherapy, 4(1),1-14,10067.

the dual diagnosis of alcohol use disorder (AUD) and depressive disorders has garnered particular attention due to its high prevalence, clinical complexity, and profound impact on patient outcomes. AUD is characterized by a problematic pattern of alcohol consumption leading to distress and impairment in various domains of life. Depressive disorders, especially major depressive disorder (MDD) and persistent depressive disorder (PDD), are the most prevalent psychiatric conditions that frequently co-occur with AUD (Grant et al., 2015). The simultaneous presence of these disorders not only exacerbates the severity of each but also increases the risk of poor prognosis, treatment resistance, and suicide (Kendler et al., 2019; Boden & Fergusson, 2011; Kessler et al., 2010). Therefore, understanding the intricate relationship between AUD and depressive disorders is crucial for the development of effective treatment strategies that address both conditions concurrently and reduce their devastating impact on individuals' lives.

2. Bidirectional Relationship Between AUD and Depressive Disorders

The relationship between AUD and depressive disorders is bidirectional, with each condition potentially exacerbating the other. Depressive disorders often precede the onset of AUD, with individuals using alcohol as a maladaptive coping mechanism to alleviate the symptoms of depression (Gilman & Abraham, 2001). In this context, alcohol consumption may offer short-term relief from negative emotions, but over time, it can lead to the development of AUD. Conversely, chronic alcohol consumption has been shown to disrupt brain chemistry and emotional regulation, which may result in or worsen depressive symptoms. This feedback loop creates a vicious cycle, complicating diagnosis and treatment. The concurrent presence of AUD and depressive disorders—referred to as dual diagnosis or comorbidity—has been associated with a range of negative outcomes, including recurrent episodes of both disorders, reduced quality of life, and higher rates of healthcare utilization (Burns & Teesson, 2002). Clinicians are thus faced with the challenge of simultaneously addressing two conditions that are deeply intertwined, requiring a comprehensive approach to treatment.

3. Genetic, Neurobiological, and Environmental Underpinnings

Despite the high prevalence and clinical significance of AUD and depressive disorder comorbidity, the mechanisms underlying this relationship remain poorly understood (Table 1). Research has suggested that genetic, neurobiological, and environmental factors contribute to the development of both conditions (Figure 3). Genetic vulnerabilities, such as polymorphisms in serotonin and dopamine receptors, may predispose individuals to both alcohol use and mood disorders (Ducci & Goldman, 2008). For example, certain genetic variants have been implicated in both alcohol craving and emotional dysregulation, which are central to the pathophysiology of AUD and depressive disorders (Figure 2).

Neuroimaging studies have identified overlapping brain regions involved in both AUD and depressive disorders. For instance, areas such as the prefrontal cortex and the amygdala, which are integral to emotional regulation, decision-making, and reward processing, have been shown to exhibit dysfunction in both conditions (Koob & Volkow, 2016). These brain structures are key to understanding the neurobiological underpinnings of the comorbidity. Disruption in the reward circuitry may lead to impaired emotional processing and poor decision-making, contributing to the persistence of both AUD and depressive disorders.

In addition to genetic and neurobiological factors, environmental influences also play a critical role. Adverse childhood experiences, such as trauma or neglect, as well as ongoing socioeconomic stressors, can increase the likelihood of developing both AUD and depressive disorders (Anda et al., 2006). These overlapping risk factors underscore the complexity of the comorbidity and highlight the need for a more nuanced understanding of how these disorders emerge and interact.

4. Diagnostic Evolution and Implications for Treatment

The transition from the fourth edition (DSM-IV) to the fifth edition (DSM-5) of the Diagnostic and Statistical Manual of Mental Disorders has significant implications for how AUD and depressive disorders are diagnosed and treated. Under the DSM-IV, alcohol use was classified into two categories: alcohol abuse and alcohol dependence. However, the DSM-5 has consolidated these categories into a single diagnosis—alcohol use disorder (AUD)—with severity determined by the number of symptoms present (American Psychiatric Association (APA), 2013). This change has had a profound impact on the understanding of AUD, particularly in its comorbidity with depressive disorders. One key modification in the DSM-5 was the removal of the legal problems criterion and the inclusion of alcohol craving as a diagnostic marker, which has influenced how clinicians assess and treat AUD.

These diagnostic changes have provided a more cohesive framework for understanding AUD in the context of depressive disorders. The DSM-5's more inclusive definition of AUD allows for a broader conceptualization of alcohol-related pathology, which is essential for understanding how alcohol use interacts with mood disorders. For example, individuals with a dual diagnosis may present with symptoms that do not fit neatly into the previous categories of alcohol abuse or dependence, necessitating more flexible diagnostic criteria to guide treatment planning.

5. Treatment Approaches for Dual Diagnosis

The treatment of individuals with both AUD and depressive disorders requires an integrated approach that addresses both

conditions simultaneously. Pharmacological interventions have shown efficacy in treating both AUD and depressive symptoms, but their effectiveness in dual diagnosis populations requires further investigation (Table 2). Medications such as naltrexone, which targets the neurobiological pathways involved in alcohol craving, and selective serotonin reuptake inhibitors (SSRIs), commonly used to treat depression, have shown promise when used in isolation (Pettinati et al., 2006). However, research is still needed to explore their combined efficacy in treating dual diagnoses.

Psychosocial interventions, including cognitive-behavioral therapy (CBT) and integrated treatment models, have emerged as promising approaches to treating dual diagnoses. These therapies address both alcohol use and depressive symptoms concurrently, helping individuals develop healthier coping strategies and improve emotional regulation. Despite their potential, significant barriers to treatment accessibility, patient engagement, and stigma remain, which hinder the widespread adoption of these interventions (Kelly et al., 2017).

Future research in this area should focus on several key areas. Longitudinal studies are needed to explore the causality of the comorbidity and the factors that contribute to the development of both AUD and depressive disorders. Understanding the trajectory of these disorders will help identify critical points for intervention. Additionally, personalized treatment approaches that consider individual differences in genetics, brain function, and environmental exposures could improve treatment outcomes. The integration of digital tools for monitoring and intervention may offer a novel direction for improving care for individuals with dual diagnoses.

This review aims to provide a comprehensive analysis of the complex relationship between AUD and depressive disorders. By examining the prevalence, progression, and treatment outcomes associated with this comorbidity, the review seeks to offer valuable insights for clinicians and researchers. Furthermore, it will identify gaps in the current literature and suggest future research directions that could improve our understanding of this dual diagnosis and lead to more effective treatment interventions. Through ongoing research and clinical innovation, we can improve the lives of individuals affected by both AUD and depressive disorders and develop more effective, integrated treatment strategies.

6. Overview of Depressive Disorders and Their Prevalence in Individuals with Alcohol Use Disorder

Depressive disorders encompass a range of conditions marked by persistent disruptions in mood, cognition, and physical functioning. These disorders are typically characterized by feelings of sadness, numbness, irritability, or hopelessness, as well as cognitive symptoms like difficulty concentrating, feelings of worthlessness, and thoughts of suicide. Physical symptoms, such as fatigue and diminished energy, also frequently occur. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), categorizes depressive disorders into several subtypes: major depressive disorder (MDD), persistent depressive disorder (PDD, also known as dysthymia), premenstrual dysphoric disorder, substance/medication-induced depressive disorder, disruptive mood dysregulation disorder, other specified depressive disorder, and unspecified depressive disorder (American Psychiatric Association (APA), 2013). This review focuses primarily on MDD, dysthymia, and substance-induced depressive disorder, as these are the most commonly studied in both the general population and individuals with alcohol use disorder (AUD).

MDD is diagnosed when a person experiences at least five symptoms, including depressed mood or anhedonia (loss of interest or pleasure in most activities), for a duration of at least two weeks. Symptoms may also include disturbances in appetite, sleep, psychomotor behavior, energy, concentration, and decision-making, alongside feelings of worthlessness or guilt, and thoughts of death or suicide. In contrast, dysthymia is a more chronic condition, typically less severe than MDD. It is characterized by a depressed mood lasting for at least two years, with at least two other symptoms, including disruptions in appetite, sleep, energy, self-esteem, concentration, or feelings of hopelessness. Alcohol-induced depressive disorder refers to depressive symptoms that occur exclusively during or shortly after alcohol intoxication or withdrawal, and these symptoms typically resolve within three to four weeks of alcohol abstinence, often causing significant distress and functional impairment (APA, 2013).

6.1 Prevalence of Depressive Disorders and AUD

MDD is the most prevalent psychiatric disorder globally, with approximately 10% to 15% of individuals affected at some point in their lifetime (Hasin et al., 2005; Kessler et al., 2011). In contrast, dysthymia affects fewer than 2% of individuals over their lifetime (Kessler et al., 2005). Among those diagnosed with AUD, MDD is the most frequently co-occurring psychiatric disorder. According to a study by Grant et al. (2004), individuals with AUD are 2.3 times more likely to have experienced MDD in the previous year and 1.7 times more likely to have had dysthymia within the same period compared to individuals without AUD. The prevalence of depressive disorders is particularly high in individuals with alcohol dependence as opposed to alcohol abuse, especially among those seeking treatment for AUD. Specifically, individuals with alcohol dependence are 3.7 times more likely to have experienced MDD and 2.8 times more likely to have had dysthymia in the past year (Grant et al., 2004).

Among individuals seeking treatment for AUD, approximately 33% meet the criteria for MDD, while 11% meet the criteria for dysthymia (Hasin et al., 2002). Alcohol-induced depressive disorder, while relatively rare in the general population, has a higher

prevalence in individuals with AUD. Schuckit et al. (1997) found that fewer than 1% of depressive disorders in individuals with substance use disorders are classified as substance-induced. However, in treatment-seeking individuals with AUD, more than 25% have experienced a substance-induced depressive episode at some point in their lives (Conner et al., 2014). Importantly, some cases initially diagnosed as alcohol-induced depression are later reclassified as independent depressive disorders when symptoms persist beyond a period of abstinence (Nunes et al., 2006).

6.2 Implications for Treatment

The co-occurrence of depressive disorders and AUD significantly complicates diagnosis and treatment. The dual burden of these conditions can exacerbate symptoms, leading to higher rates of treatment resistance, poorer prognosis, and increased suicide risk (Greenfield et al., 1998). The high prevalence of MDD and dysthymia in individuals with AUD highlights the need for integrated treatment approaches that address both disorders simultaneously. Pharmacological interventions, such as selective serotonin reuptake inhibitors (SSRIs) for depression and medications like naltrexone for AUD, have shown efficacy in treating each disorder separately (Pettinati et al., 2006). However, more research is needed to determine the most effective strategies for treating individuals with dual diagnoses.

Depressive disorders, particularly MDD and dysthymia, are highly prevalent in individuals with AUD, making the co-occurrence of these disorders a significant public health concern. Alcohol-induced depressive disorder, while less common, is notably more frequent among treatment-seeking patients with AUD. The complex relationship between these disorders demands integrated treatment approaches that simultaneously address both conditions. As our understanding of the mechanisms underlying these comorbidities improves, more effective interventions can be developed, ultimately improving outcomes for individuals struggling with both AUD and depressive disorders.

6.3 Disproportionately Affected Populations

Certain demographic groups are disproportionately affected by the co-occurrence of Alcohol Use Disorder (AUD) and depressive disorders. For instance, women are 1.5 to 2 times more likely to experience major depressive disorder over their lifetime than men (Kessler, 2003). Additionally, women with DSM-IV AUD are more likely than men with the same diagnosis to meet criteria for major depressive disorder or dysthymia (Kessler, Crum, Warner, et al., 1997; Khan, Okuda, Hasin, et al., 2013). This trend is not limited to prevalence but extends to the course of these disorders. For example, a longitudinal study found that depression in women predicted the development of alcohol problems, whereas this was not the case for men (Moscato, Russell, Zielezny, et al., 1997). Retrospective studies further support these findings, showing that women are more likely to experience depression before developing AUD, while men typically experience AUD before depression (Hanna & Grant, 1997; Prescott, Aggen, & Kendler, 2000).

Racial and ethnic differences also contribute to the prevalence and outcomes of co-occurring AUD and depressive disorders, although research has been limited by small sample sizes, making group comparisons difficult (Smith, Stinson, Dawson, et al., 2006). However, substantial evidence points to disparities in healthcare access, particularly among racial and ethnic minority groups. While treatment access for AUD is similar across racial and ethnic groups, Black or Latino individuals are significantly less likely to receive treatment for mood and anxiety disorders, or integrated care for both mental health and substance use disorders, compared to White individuals (Hatzenbuehler, Keyes, Narrow, et al., 2008; Nam, Matejkowski, & Lee, 2017).

6.4 Pathways to Co-Occurrence

The co-occurrence of AUD and depressive disorders can arise through several pathways, including (1) depressive disorders increasing the risk of AUD, (2) AUD increasing the risk of depressive disorders, and (3) shared common risk factors or pathophysiological mechanisms (Hasin, Liu, Nunes, et al., 2002). Although evidence supports all three pathways, more research is necessary to fully understand the mechanisms behind their co-occurrence.

7. Etiology of Co-occurring Alcohol Use Disorder (AUD) and Depressive Disorders

Research on the development of co-occurring Alcohol Use Disorder (AUD) and depressive disorders has been primarily based on retrospective and longitudinal studies that examine the age of onset for each condition. These studies have produced inconsistent findings. Some suggest that depressive disorders tend to precede the onset of AUD (Abraham & Fava, 1999), while others indicate that AUD typically precedes depressive disorders (Fergusson, Boden, & Horwood, 2009). Additionally, some research suggests that the sequence of onset may vary by gender, with women generally experiencing an earlier onset of depression than men (Prescott, Aggen, & Kendler, 2000).

Research into the onset of substance use during adolescence and young adulthood has shown that internalizing symptoms, such as depression and anxiety, typically serve as protective factors against alcohol misuse during adolescence (Colder, Frndak, Lengua, et al., 2018). However, the relationship between internalizing symptoms and alcohol use is influenced by several moderating factors, including the presence of both internalizing and externalizing symptoms (e.g., impulsivity and aggression), motivations for substance use, and gender (Crum, Mojtabai, Lazareck, et al., 2013). Specifically, studies have found that internalizing symptoms serve as a risk factor for the development of AUD in women but not in men (Foster, Hicks, Iacono, et al., 2015).

Moreover, AUD has been found to increase the risk of developing depressive symptoms and disorders. A review of existing literature demonstrated that regular or heavy alcohol consumption during adolescence is linked to an increased risk of depressive symptoms (Pedrelli, Shapero, Archibald, et al., 2016). Among adults, DSM-IV AUD has been associated with a heightened risk for the onset of major depressive disorder and dysthymia (Falk, Yi, & Hilton, 2008; Kessler et al., 2005). Additionally, there is emerging evidence suggesting that AUD and depressive disorders may share common pathophysiological mechanisms, although research in this area remains limited. Genetic studies have indicated that AUD and depressive disorders might share certain genetic vulnerabilities (Andersen et al., 2017; Zhou et al., 2017). Various candidate systems and processes have been proposed as potential shared mechanisms, including dysfunctions in reward and stress systems (Renoir, Pang, & Lanfumey, 2012). Studies of depressive disorders have indicated that specific symptom profiles may correlate with distinct underlying pathophysiological mechanisms. For instance, variations in brain electrical activity (measured by electroencephalogram) have been associated with different symptom types (Webb, Dillon, Pechtel, et al., 2016).

Given the heterogeneous nature of major depressive disorder, which encompasses 227 potential symptom combinations (Boschloo, Vogelzangs, van den Brink, et al., 2012), it is crucial to account for the variety of symptom profiles when considering the co-occurrence of AUD and depressive disorders. This heterogeneity underscores the complexity of understanding the relationship between these two conditions, highlighting the need for further research to unravel the shared pathophysiology between AUD and depressive disorders.

7.1 Course and Prognosis of Co-occurring AUD and Depressive Disorders

The prognosis for individuals with co-occurring AUD and depressive disorders is highly variable, influenced by factors such as the age of onset and severity of each disorder. Severe alcohol dependence, as defined by DSM-IV, is associated with the persistence of depressive disorders, whereas alcohol abuse does not exhibit the same association (Davis et al., 2010). Additionally, the way depression is measured affects the link between depressive disorders and AUD outcomes. Major depressive disorder is typically associated with worse treatment outcomes for AUD (Hasin et al., 1996; Sullivan, Fiellin, & O'Connor, 2005), while more severe depressive symptoms do not consistently correlate with worse outcomes when compared to less severe depressive symptoms (Liappas, Paparrigopoulos, Tzavellas, et al., 2002). Interestingly, depressive symptoms tend to improve significantly after a period of alcohol abstinence (usually 3 to 4 weeks), which may explain the lack of a clear link between depressive symptoms and drinking outcomes outside of the depressive disorder context (Crum et al., 2013).

Longitudinal data on whether AUD exacerbates depression outcomes presents mixed results. Some studies suggest that AUD worsens depression outcomes, while others show no significant difference (Fergusson et al., 2009). However, large-scale studies indicate a positive correlation between recovery from both disorders, with remission from one condition strongly associated with remission from the other. A multisite trial (N = 2,876) on the treatment of depressive disorders found that patients with co-occurring substance use disorders were less likely to achieve remission from depression and took longer to do so compared to individuals without substance use disorders (Hasin et al., 1996). Although alcohol-induced depressive disorder typically resolves upon cessation of alcohol use, it has been shown to increase the risk of developing major depressive disorder (Falk et al., 2008). Furthermore, patients with alcohol-induced depressive disorders experience worse alcohol-related outcomes compared to those with other types of depressive disorders (Samet et al., 2013).

8. Treatment of Co-Occurring Alcohol Use Disorder (AUD) and Depressive Disorders

The co-occurrence of alcohol use disorder (AUD) and depressive disorders presents a complex clinical challenge, often requiring integrated treatment strategies. A variety of randomized trials have investigated treatments for these comorbid conditions, focusing on both pharmacological and psychotherapeutic interventions. This section examines these treatment modalities, analyzing their efficacy in addressing both depressive and AUD symptoms.

8.1 Medication Trials

Medication-based treatments for co-occurring AUD and depression have predominantly focused on antidepressants, with several meta-analyses synthesizing findings from randomized trials (Agabio, Trogu, & Pani, 2018; Iovieno et al., 2011; Nunes & Levin, 2004) (Figure 1). These studies suggest that antidepressant medications are generally more effective than placebo in alleviating depressive symptoms in individuals with both AUD and depression. The magnitude of the benefit is often comparable to that observed in studies involving patients with depression alone (Nunes & Levin, 2004). However, limited trials directly compare different treatments, and most studies typically involve a single antidepressant compared to a placebo, leaving gaps in understanding the comparative effectiveness of active treatments (Nunes & Levin, 2004).

Among the antidepressants studied, older medications like tricyclic antidepressants (TCAs) have shown more robust effects on depressive symptoms compared to newer medications such as selective serotonin reuptake inhibitors (SSRIs) (Iovieno et al., 2011).

This difference may be due, in part, to a more substantial placebo response observed in SSRIs trials, which complicates the interpretation of efficacy data (Nunes & Levin, 2004). Despite these findings, the impact of antidepressants on alcohol consumption is generally modest, with mixed results across studies (Nunes & Levin, 2004; Torrens et al., 2005). In some cases, reductions in depressive symptoms appear to mediate the effects of antidepressants on drinking behaviors, suggesting that alleviating depression may play a crucial role in improving alcohol-related outcomes (McHugh & Weiss, 2019).

Studies involving other pharmacological treatments for AUD, such as naltrexone and acamprosate, have also shown promise in managing both AUD and depressive symptoms. Naltrexone, which is often used to reduce alcohol cravings, has been demonstrated to reduce both alcohol consumption and depressive symptoms in individuals with co-occurring AUD and depression (Petrakis et al., 2007; Salloum et al., 1998). A meta-analysis examining the efficacy of acamprosate in AUD treatment also showed positive effects on depressive symptoms, particularly when individuals achieved alcohol abstinence (Lejoyeux & Lehert, 2011). Furthermore, combining antidepressants with medications for AUD has yielded encouraging results. For instance, the combination of sertraline (an SSRI) with naltrexone has been associated with reductions in both depressive symptoms and alcohol use (Pettinati et al., 2010), and combining escitalopram (another SSRI) with acamprosate has also shown benefits in managing both conditions (Witte et al., 2012).

8.2 Psychosocial Treatments and Mutual Help

In addition to pharmacological interventions, numerous studies have explored the role of behavioral and psychosocial therapies in treating co-occurring AUD and depressive disorders. However, many of these studies have been limited by small sample sizes, which affect the generalizability of their findings. A meta-analysis examining the combined use of motivational interviewing and cognitive behavioral therapy (CBT) for treating AUD and depression found significant, although modest, improvements in both depressive symptoms and alcohol consumption outcomes (Riper et al., 2014). These findings align with earlier research examining other forms of psychotherapy, such as interpersonal therapy (IPT) and CBT, which also reported modest but positive effects on depression and alcohol-related outcomes (Hesse, 2009).

A promising approach to the treatment of co-occurring AUD and depression involves transdiagnostic behavioral interventions that target both conditions simultaneously. One such intervention, behavioral activation, focuses on increasing engagement with rewarding activities to improve mood and reduce depressive symptoms. Behavioral activation has been shown to be effective for both depressive disorders (Dimidjian et al., 2006) and AUD (Daughters et al., 2018), suggesting its potential as a treatment for co-occurring conditions. A modified version of behavioral activation, known as "Life Enhancement Treatment for Substance Use" (LETS ACT), has demonstrated efficacy in reducing substance-related consequences and increasing the likelihood of abstinence in individuals with alcohol dependence (Daughters et al., 2018).

Integrated treatment approaches have also been developed, including those combining CBT for depressive and substance use disorders. Studies indicate that integrated CBT can result in greater reductions in alcohol use compared to traditional treatments, although the depression outcomes were similar to those achieved through 12-step facilitation therapy (Lydecker et al., 2010). This suggests that integrated interventions may be more effective for addressing alcohol use outcomes, while traditional therapies may be equally effective for managing depression.

Psychotherapies may also explain some of the placebo effects observed in medication trials. In trials where participants receiving placebo medications also underwent psychotherapy, response rates were often higher than in placebo-only trials, suggesting that psychotherapy might provide antidepressant effects independent of the medication used (Nunes et al., 1998). This highlights the importance of incorporating psychotherapy into treatment regimens for co-occurring disorders, as it may enhance the efficacy of medications.

Mutual-help groups, such as Alcoholics Anonymous (AA), also represent a valuable adjunct to formal treatments for co-occurring AUD and depression. Research has shown that participation in AA meetings is associated with a reduction in depressive symptoms, and in some cases, this reduction in depression has been found to mediate the relationship between AA attendance and improvements in alcohol consumption outcomes (Wilcox & Tonigan, 2018). This suggests that the emotional support and sense of community provided by AA may be instrumental in improving both depression and alcohol use.

The treatment of co-occurring AUD and depressive disorders requires a multifaceted approach that includes both pharmacological and psychosocial interventions. Antidepressant medications, particularly when combined with medications for AUD like naltrexone and acamprosate, have shown promise in managing both conditions. Psychosocial treatments, including behavioral activation and integrated CBT, have also demonstrated efficacy in reducing depressive symptoms and alcohol use. Additionally, mutual-help groups like AA provide valuable support and may further enhance treatment outcomes. Future research should focus on directly comparing different treatment options and examining the mechanisms through which these interventions improve both alcohol and depression outcomes.

8.3 Future Research Directions in the Treatment of Co-occurring Alcohol Use Disorder and Depressive Disorders

Despite significant advancements in understanding the etiology, progression, and treatment of co-occurring alcohol use disorder (AUD) and depressive disorders, considerable gaps remain in our knowledge. These gaps present valuable opportunities for future research aimed at improving treatment outcomes and enhancing our understanding of the mechanisms underlying these complex comorbidities. This section explores key areas for future research, including optimal treatments, heterogeneity within affected populations, innovative technologies, gender and racial disparities, and more precise diagnostic and treatment strategies.

9. Optimizing Treatment Strategies

One major avenue for future research is the identification and development of more effective treatments for individuals with co-occurring AUD and depressive disorders. While existing treatments, such as medication and behavioral therapy, have shown some promise, response rates remain relatively modest (Nunes et al., 2004; Iovieno et al., 2011). Research focused on understanding the characteristics of individuals who do not respond to current treatments could help refine personalized approaches that are more effective. This could include investigations into genetic, psychological, and social factors that influence treatment outcomes, allowing for targeted interventions that could improve overall effectiveness.

Preclinical studies suggest common disruptions in reward and stress processing in both AUD and depression, which may contribute to the observed variability in clinical outcomes (Renoir, Pang, & Lanfumey, 2012). These disruptions offer a potential target for novel treatments, yet more research is needed to translate these findings into clinical applications. Additionally, understanding the mechanisms behind symptom variability is essential for developing more tailored interventions. For example, AUD that emerges as a coping mechanism in response to depression may require different treatment strategies than AUD that develops prior to or independently of depression (Fergusson, Boden, & Horwood, 2009).

10. Gender and Racial Disparities in Research

Another critical area for future research is the role of gender and ethnicity in the co-occurrence of AUD and depressive disorders. Historically, women have been underrepresented in studies of these conditions, especially in early research (Kessler, 2003; Khan et al., 2013). A better understanding of how gender influences the development and progression of AUD and depression could enhance the development of gender-specific treatments. Women are more susceptible to depression, and research suggests that hormonal fluctuations, such as those observed in premenstrual dysphoric disorder, may contribute to increased vulnerability (Kessler et al., 1997). Investigating the intersection of AUD, depression, and hormonal changes in women could provide valuable insights for personalized treatment approaches.

Similarly, research on the co-occurrence of AUD and depressive disorders among racial and ethnic minorities is urgently needed. These populations often face disparities in access to care and are frequently underrepresented in studies of these conditions (Smith et al., 2006; Hatzenbuehler, Keyes, Narrow, et al., 2008). Understanding how cultural factors, genetic predispositions, and environmental stressors contribute to the development of these co-occurring disorders will help improve treatment accessibility and outcomes for these groups. Additionally, racial and ethnic minorities may experience different social pressures and stigma related to both alcohol use and mental health disorders, which could further exacerbate treatment challenges (Nam, Matejkowski, & Lee, 2017).

11. Innovative Technologies in Research

The incorporation of innovative technologies, such as ecological momentary assessment (EMA) and multimodal neuroimaging, holds great promise for advancing research in the field of co-occurring AUD and depressive disorders. EMA allows for the real-time collection of data on mood and alcohol use, providing insights into the dynamic interactions between these factors over time (Crum et al., 2013). This approach can help identify patterns of alcohol consumption and mood fluctuations that may be difficult to detect using traditional research methods. Furthermore, the use of neuroimaging techniques, such as functional magnetic resonance imaging (fMRI) and positron emission tomography (PET), can illuminate the neural correlates of co-occurring AUD and depressive disorders, offering insights into the brain regions involved in both conditions (Webb et al., 2016).

Research utilizing these technologies could also benefit from dimensional measures rather than discrete categorical approaches. Dimensional assessments, which capture the full spectrum of symptoms and severity, including subclinical manifestations, would provide a more comprehensive understanding of the complex interplay between alcohol use and depression (Boschloo et al., 2012). This approach could also improve the precision of diagnostic tools and treatment strategies, as it would better reflect the continuous nature of these disorders.

12. Diagnosing and Treating Co-occurring Disorders

Diagnosing and treating co-occurring AUD and depressive disorders presents significant challenges due to overlapping symptoms, such as the depressant effects of alcohol and the shared features of alcohol withdrawal and depression, including insomnia and psychomotor agitation (Grant et al., 2004). The DSM-5 offers



Figure 1. Potential medications for alcohol use disorders and their signaling pathways. FDA-approved drugs and other medications, such as anticonvulsants and some off-label medications that are used or repurposed for the treatment of AUDs.



Figure 2. Effects of medications and hormones on various receptors in the brain regions to inhibit alcohol intake. Drugs, hormones and their receptors in the brain inhibiting alcohol intake.

Table 1. Genetic and Psychological Mechanisms of Alcohol Dependence and Major Depressive Disorder

Study	Genetic Mechanisms	Psychological Mechanisms	Key Findings	Treatment Implications	References
Andersen et al. (2017)	Polygenic risk scores linked alcohol dependence and major depression	Depression as a risk factor for alcohol dependence	Identified shared genetic pathways	Personalized medicine could improve treatment	Andersen, A. M., Pietrzak, R. H., Kranzler, H. R., et al. (2017).
Kuo et al. (2006)	Temporal relationship of alcohol dependence and depression onset	Alcohol dependence exacerbates depression	Alcohol dependence often precedes major depression	Early interventions could prevent dual diagnoses	Kuo, P. H., Gardner, C. O., Kendler, K. S., et al. (2006).
Zhou et al. (2017)	Genetic variants associated with comorbidity	Comorbid disorders have shared genetic risks	Genetic risk for both conditions exists	Targeted pharmacogenetic treatments	Zhou, H., Polimanti, R., Yang, B. Z., et al. (2017).
Renoir et al. (2012)	Serotonergic dysregulation linked to withdrawal	Drug withdrawal-induced depression	Depressive symptoms worsen with substance withdrawal	Focus on serotonin pathways in treatment	Renoir, T., Pang, T. Y., & Lanfumey, L. (2012).
Sullivan et al. (2005)	No significant genetic studies identified	Co-occurring alcohol problems worsen depression	Alcohol problems increase severity of depression	Address both conditions in treatment	Sullivan, L. E., Fiellin, D. A., O'Connor, P. G. (2005).

Table 2. Treatment Efficacy for Alcohol Dependence and Major Depression

Study	Treatment Type	Patient Population	Outcome	Key Findings	References
Agabio et al. (2018)	Antidepressants	Comorbid depression and alcohol dependence	Mixed outcomes	Antidepressants show limited efficacy for dual diagnosis	Agabio, R., Trogu, E., & Pani, P. P. (2018).
Iovieno et al. (2011)	Antidepressants (Placebo-controlled)	Depression with alcohol use disorder	Positive effects	Antidepressants help manage both conditions	Iovieno, N., Tedeschini, E., Bentley, K. H., et al. (2011).
Petrakis et al. (2007)	Naltrexone and disulfiram	Alcohol dependence and depression	Effective for alcohol dependence	Combined pharmacotherapy improves depression and alcohol use	Petrakis, I., Ralevski, E., Nich, C., et al. (2007).
Lejoyeux & Lehert (2011)	Acamprosate	Alcohol use disorders and depression	Positive effects	Acamprosate showed benefits in depression co-occurring with alcohol use	Lejoyeux, M., & Lehert, P. (2011).
Riper et al. (2014)	Cognitive Behavioral Therapy + Motivational Interviewing	Comorbid alcohol use disorder and depression	Effective	Integrated therapy improved both conditions	Riper, H., Andersson, G., Hunter, S. B., et al. (2014).

Table 3. Summary of Key Studies on the Relationship Between Alcohol Use and Major Depression

Study	Year	Sample Size	Key Findings	Link to Alcohol Use	Key Outcomes
Andersen et al.	2017	Large cohort	Polygenic scores linked depression with alcohol dependence risk	Genetic correlation	Depression and alcohol dependence share genetic risk factors
Kuo et al.	2006	Large cohort	Temporal onset of alcohol dependence and major depression	Alcohol dependence and major depression comorbidity	Alcohol dependence may precede depression onset
Zhou et al.	2017	Large cohort	Genetic risk factors identified for both alcohol dependence and depression	Genetic risk variants	Shared genetic factors increase comorbidity risk
Renoir et al.	2012	Animal models	Drug withdrawal-induced depression linked with serotonin changes	Withdrawal and serotonin	Drug withdrawal models suggest serotonergic changes lead to depression
Webb et al.	2016	Human study	Neural correlates of depression and alcohol use disorders	Alcohol use and depression	Identified neural mechanisms in alcohol dependence and depression comorbidity

Table 4. Treatment Strategies and Efficacy for Comorbid Alcohol Use and Major Depression

Treatment Study	Year	Treatment Type	Study Design	Efficacy	Key Findings
Nunes et al.	2004	Antidepressant therapy	Meta-analysis	Moderate	Antidepressants show effectiveness in treating depression in alcohol use disorder patients
Petrakis et al.	2007	Naltrexone and disulfiram	Clinical trial	Positive	Combined treatment improves outcomes for patients with both alcohol dependence and depression
Salloum et al.	1998	Naltrexone therapy	Pilot study	Positive	Naltrexone shown effective for alcohol dependence in depressed individuals
Dimidjian et al.	2006	Behavioral activation	Randomized trial	High	Behavioral activation is effective for treating depression in alcohol-dependent individuals
Kelly et al.	2012	Integrated treatment	Case study review	High	Integrated treatment programs help manage comorbid depression and alcohol use disorders



Figure 3. **A)** Distribution of Key Study Findings on Alcohol-Depression Comorbidity, highlighting the main findings like genetic risk factors, withdrawal changes, neural mechanisms, and temporal onset analysis. **B)** Sample Sizes in Key Studies on Alcohol-Depression Comorbidity, showing the number of participants in significant studies. **C)** Treatment Efficacy for Alcohol-Depression Comorbidity, breaking down the effectiveness of treatments like antidepressants, naltrexone, behavioral activation, and integrated treatment. **D)** Frequency of Study Design Types in Alcohol-Depression Comorbidity Research, depicting how often different study designs (e.g., meta-analysis, clinical trials) were used.

guidance in differentiating between substance-induced disorders and primary depressive disorders, but the diagnostic process remains complex and requires careful consideration of the timing and context of symptoms (American Psychiatric Association, 2013). A careful assessment of symptoms outside of drinking or withdrawal periods, with the inclusion of collateral information, is essential for making accurate diagnoses and ensuring appropriate treatment (Hasin et al., 2006).

Research into more refined diagnostic criteria and biomarkers for these conditions is crucial to reduce diagnostic ambiguity. The use of advanced neuroimaging techniques and genetic testing may play an important role in identifying specific biomarkers associated with co-occurring AUD and depressive disorders, potentially facilitating earlier and more accurate diagnoses (Zhou et al., 2017). Moreover, continued investigation into the effectiveness of different treatment approaches, including pharmacological interventions such as naltrexone and antidepressants (Petrakis et al., 2007; Agabio, Trogu, & Pani, 2018), as well as behavioral therapies like behavioral activation (Lejoyeux & Lehert, 2011), is necessary to identify the most effective combination of therapies for this population.

13. Nursing Interventions for Co-Occurring Alcohol Use Disorder (AUD) and Depressive Disorders: A Comprehensive Approach

The co-occurrence of Alcohol Use Disorder (AUD) and depressive disorders presents a complex challenge for both diagnosis and treatment (Table 3). These dual conditions are often intertwined, compounding the severity of each and creating a vicious cycle that significantly impacts the prognosis and quality of life for affected individuals. Nursing interventions for such patients require a multifaceted approach that addresses both the psychological and physical aspects of the disorders. Nurses play a pivotal role in managing the intricacies of these conditions through personalized care, empathetic support, and coordination with the broader healthcare team.

A key aspect of effective nursing care is the establishment of a therapeutic relationship based on trust and empathy. This foundational relationship enables patients to feel supported, which is crucial for encouraging active participation in treatment. Nurses must assess both the mental health history and substance use patterns of individuals, carefully noting the severity of alcohol dependence and depressive symptoms. This thorough assessment forms the basis for tailoring a treatment plan that will address the patient's unique needs and challenges. By gathering insights into the history of alcohol use and depressive symptoms, nurses can ensure that interventions are focused and relevant to the individual's condition.

One of the most critical nursing interventions for patients with co-occurring AUD and depressive disorders is the monitoring of withdrawal symptoms. Alcohol withdrawal can trigger or exacerbate depressive symptoms, making careful observation essential. Nurses must be familiar with the signs of alcohol withdrawal, including tremors, anxiety, agitation, and hallucinations. Through vigilant monitoring, nurses can identify when symptoms are worsening and respond accordingly. In collaboration with the healthcare team, nurses can also administer medications such as benzodiazepines to alleviate withdrawal symptoms or antidepressants to manage depressive symptoms (Table 4). However, these medications should be prescribed carefully, as they may have complex interactions with one another.

Psychosocial support is another cornerstone of effective nursing intervention. Nurses can employ various cognitive-behavioral strategies to help patients challenge negative thought patterns and improve their coping skills. Techniques such as problem-solving and reframing can empower patients to manage stressors and triggers more effectively. Behavioral activation, which encourages patients to engage in rewarding and meaningful activities, is particularly beneficial for those with depression. Through this approach, nurses can help patients identify and re-engage in hobbies, social activities, and other behaviors that promote a sense of accomplishment and well-being.

Moreover, nurses should educate patients on the importance of a structured routine, regular social interactions, and healthy lifestyle choices, all of which can have a positive impact on both mood and alcohol recovery. This education fosters a sense of agency in the patient and enhances their motivation to remain engaged in treatment. Encouraging patients to adopt these positive lifestyle changes is essential for long-term recovery and emotional stability.

Collaboration with other healthcare providers is vital in managing dual diagnoses effectively. Nurses should coordinate care with addiction counselors, mental health professionals, and primary care providers to ensure a holistic and integrated treatment approach. This teamwork ensures that all aspects of the patient's condition are addressed simultaneously, leading to more comprehensive care. Furthermore, nurses can assist patients in accessing support groups, such as Alcoholics Anonymous (AA), which provide valuable peer support and a sense of community for individuals struggling with alcohol addiction.

The need for integrated treatment is also reflected in the pharmacological and psychotherapeutic approaches that are employed. Antidepressant medications, while effective in alleviating depressive symptoms, often have mixed results when it comes to alcohol consumption. Research suggests that older classes of antidepressants, such as tricyclic antidepressants, may be more effective than newer options like selective serotonin reuptake inhibitors (SSRIs), though further research is needed to determine the most effective pharmacological treatments for this dual diagnosis. Additionally, psychotherapies such as cognitive-

behavioral therapy (CBT) and integrated care models have proven beneficial in treating both AUD and depressive symptoms concurrently. These therapies aim to reduce alcohol use while simultaneously addressing the cognitive and emotional aspects of depression.

The prognosis for individuals with both AUD and depressive disorders is highly variable. Some research shows that achieving alcohol abstinence can lead to significant improvements in depressive symptoms. However, for many patients, the persistence of depressive symptoms continues to hinder alcohol recovery. This highlights the importance of addressing both disorders together in treatment, as failure to manage depressive symptoms may lead to relapse or poor alcohol-related outcomes.

14. Conclusion

In conclusion, nursing interventions for patients with co-occurring AUD and depressive disorders must be holistic and tailored to the individual's needs. The interventions should incorporate a comprehensive assessment, monitoring of withdrawal symptoms, psychosocial support, promotion of behavioral activation, and close collaboration with a multidisciplinary team. By addressing both the mental and physical aspects of these conditions, nurses can help patients achieve better outcomes. Future research should explore shared pathophysiological mechanisms between AUD and depression to create more effective treatment options. Furthermore, greater focus is needed on socio-cultural factors that may influence treatment outcomes, particularly in underrepresented or minority populations. Integrated treatment protocols, informed by ongoing research, have the potential to provide more personalized and effective care, ensuring that patients with co-occurring AUD and depressive disorders can achieve lasting recovery and improved mental health.

Author contributions

M.T.A. conceptualized the study and provided oversight for the research process. R.M.A. and A.A.H.A. were responsible for the methodology and data collection. M.S.A., S.S.A., and A.M.A. contributed to the analysis and interpretation of data. K.O.A.A., M.M.A., and S.H.S.A. participated in manuscript drafting and revision. T.G.T.A. and H.B.B.A. ensured the accuracy and integrity of the work. A.H.M.A. and H.D.T.A. contributed to the final review and approval of the manuscript. All authors read and approved the final version of the manuscript.

Acknowledgment

The authors were grateful to their department.

Competing financial interests

The authors have no conflict of interest.

References

Abraham, H. D., & Fava, M. (1999). Order of onset of substance abuse and depression in a sample of depressed outpatients. Comprehensive Psychiatry, 40(1), 44–50. https://doi.org/10.1016/s0010-440x(99)90076-7

Agabio, R., Trogu, E., & Pani, P. P. (2018). Antidepressants for the treatment of people with co-occurring depression and alcohol dependence. Cochrane Database of Systematic Reviews, 4, CD008581. https://doi.org/10.1002/14651858.CD008581.pub2

American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). American Psychiatric Association.

American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). American Psychiatric Association.

Andersen, A. M., Pietrzak, R. H., Kranzler, H. R., et al. (2017). Polygenic scores for major depressive disorder and risk of alcohol dependence. JAMA Psychiatry, 74(11), 1153–1160. https://doi.org/10.1001/jamapsychiatry.2017.2269

Boschloo, L., Vogelzangs, N., van den Brink, W., et al. (2012). Alcohol use disorders and the course of depressive and anxiety disorders. The British Journal of Psychiatry, 200(6), 476–484. https://doi.org/10.1192/bjp.bp.111.097550

Colder, C. R., Frndak, S., Lengua, L. J., et al. (2018). Internalizing and externalizing problem behavior: A test of a latent variable interaction predicting a two-part growth model of adolescent substance use. Journal of Abnormal Child Psychology, 46(2), 319–330. https://doi.org/10.1007/s10802-017-0277-6

Conner, K. R., Gamble, S. A., Bagge, C. L., et al. (2014). Substance-induced depression and independent depression in proximal risk for suicidal behavior. Journal of Studies on Alcohol and Drugs, 75(4), 567–572. https://doi.org/10.15288/jsad.2014.75.567

Crum, R. M., Mojtabai, R., Lazareck, S., et al. (2013). A prospective assessment of reports of drinking to self-medicate mood symptoms with the incidence and persistence of alcohol dependence. JAMA Psychiatry, 70(7), 718–726. https://doi.org/10.1001/jamapsychiatry.2013.1098

Daughters, S. B., Magidson, J. F., Anand, D., et al. (2018). The effect of a behavioral activation treatment for substance use on post-treatment abstinence: A randomized controlled trial. Addiction, 113(3), 535–544. https://doi.org/10.1111/add.14049

Davis, L. L., Wisniewski, S. R., Howland, R. H., et al. (2010). Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes. Drug and Alcohol Dependence, 107(2–3), 161–170. https://doi.org/10.1016/j.drugalcdep.2009.10.003

Dimidjian, S., Hollon, S. D., Dobson, K. S., et al. (2006). Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression. Journal of Consulting and Clinical Psychology, 74(4), 658–670. https://doi.org/10.1037/0022-006X.74.4.658

Falk, D. E., Yi, H. Y., & Hilton, M. E. (2008). Age of onset and temporal sequencing of lifetime DSM-IV alcohol use disorders relative to comorbid mood and anxiety disorders. Drug and Alcohol Dependence, 94(1–3), 234–245. https://doi.org/10.1016/j.drugalcdep.2007.11.022

Farren, C. K., Scimeca, M., Wu, R., et al. (2009). A double-blind, placebo-controlled study of sertraline with naltrexone for alcohol dependence. Drug and Alcohol

Dependence, 99(1–3), 317–321. https://doi.org/10.1016/j.drugalcdep.2008.06.006

Fergusson, D. M., Boden, J. M., & Horwood, L. J. (2009). Tests of causal links between alcohol abuse or dependence and major depression. Archives of General Psychiatry, 66(3), 260–266. https://doi.org/10.1001/archgenpsychiatry.2008.543

Foster, K. T., Hicks, B. M., Iacono, W. G., et al. (2015). Gender differences in the structure of risk for alcohol use disorder in adolescence and young adulthood. Psychological Medicine, 45(14), 3047–3058. https://doi.org/10.1017/S0033291715001014

Grant, B. F., Stinson, F. S., Dawson, D. A., et al. (2004). Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Archives of General Psychiatry, 61(8), 807–816. https://doi.org/10.1001/archpsyc.61.8.807

Greenfield, S. F., Weiss, R. D., Muenz, L. R., et al. (1998). The effect of depression on return to drinking: A prospective study. Archives of General Psychiatry, 55(3), 259–265. https://doi.org/10.1001/archpsyc.55.3.259

Hanna, E. Z., & Grant, B. F. (1997). Gender differences in DSM-IV alcohol use disorders and major depression as distributed in the general population: Clinical implications. Comprehensive Psychiatry, 38(4), 202–212. https://doi.org/10.1016/s0010-440x(97)90028-6

Hasin, D. S., Goodwin, R. D., Stinson, F. S., et al. (2005). Epidemiology of major depressive disorder: Results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Archives of General Psychiatry, 62(10), 1097–1106. https://doi.org/10.1001/archpsyc.62.10.1097

Hasin, D. S., Tsai, W. Y., Endicott, J., et al. (1996). Five-year course of major depression: Effects of comorbid alcoholism. Journal of Affective Disorders, 41(1), 63–70. https://doi.org/10.1016/0165-0327(96)00068-7

Hasin, D., Liu, X., Nunes, E., et al. (2002). Effects of major depression on remission and relapse of substance dependence. Archives of General Psychiatry, 59(4), 375–380. https://doi.org/10.1001/archpsyc.59.4.375

Hatzenbuehler, M. L., Keyes, K. M., Narrow, W. E., et al. (2008). Racial/ethnic disparities in service utilization for individuals with co-occurring mental health and substance use disorders in the general population: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Journal of Clinical Psychiatry, 69(7), 1112–1121. https://doi.org/10.4088/jcp.v69n0711

Hesse, M. (2009). Integrated psychological treatment for substance use and co-morbid anxiety or depression vs. treatment for substance use alone: A systematic review of the published literature. BMC Psychiatry, 9, 6. https://doi.org/10.1186/1471-244X-9-6

Iovieno, N., Tedeschini, E., Bentley, K. H., et al. (2011). Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: A meta-analysis of placebo-controlled randomized trials. Journal of Clinical Psychiatry, 72(8), 1144–1151. https://doi.org/10.4088/JCP.10m06217

Kelly, T. M., Daley, D. C., & Douaihy, A. B. (2012). Treatment of substance-abusing patients with comorbid psychiatric disorders. Addictive Behaviors, 37(1), 11–24. https://doi.org/10.1016/j.addbeh.2011.09.010

Kessler, R. C. (2003). Epidemiology of women and depression. Journal of Affective Disorders, 74(1), 5–13. https://doi.org/10.1016/s0165-0327(02)00426-3

Kessler, R. C., Chiu, W. T., Demler, O., et al. (2005). Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry, 62(6), 617–627. https://doi.org/10.1001/archpsyc.62.6.617

Kessler, R. C., Crum, R. M., Warner, L. A., et al. (1997). Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Archives of General Psychiatry, 54(4), 313–321. https://doi.org/10.1001/archpsyc.1997.01830160031005

Kessler, R. C., Ormel, J., Petukhova, M., et al. (2011). Development of lifetime comorbidity in the World Health Organization world mental health surveys. Archives of General Psychiatry, 68(1), 90–100. https://doi.org/10.1001/archgenpsychiatry.2010.180

Khan, S., Okuda, M., Hasin, D. S., et al. (2013). Gender differences in lifetime alcohol dependence: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Alcoholism: Clinical and Experimental Research, 37(10), 1696–1705. https://doi.org/10.1111/acer.12158

Kuo, P. H., Gardner, C. O., Kendler, K. S., et al. (2006). The temporal relationship of the onsets of alcohol dependence and major depression: Using a genetically informative study design. Psychological Medicine, 36(8), 1153–1162. https://doi.org/10.1017/S0033291706007860

Lejoyeux, M., & Lehert, P. (2011). Alcohol-use disorders and depression: Results from individual patient data meta-analysis of the acamprosate-controlled studies. Alcohol and Alcoholism, 46(1), 61–67. https://doi.org/10.1093/alcalc/agq077

Liappas, J., Paparrigopoulos, T., Tzavellas, E., et al. (2002). Impact of alcohol detoxification on anxiety and depressive symptoms. Drug and Alcohol Dependence, 68(2), 215–220. https://doi.org/10.1016/s0376-8716(02)00195-3

Lydecker, K. P., Tate, S. R., Cummins, K. M., et al. (2010). Clinical outcomes of an integrated treatment for depression and substance use disorders. Psychology of Addictive Behaviors, 24(3), 453–465. https://doi.org/10.1037/a0019943

Millan, M. J., & Olfson, M. (2007). The implications of depression and comorbid substance use disorder in treatment decision-making. JAMA, 297(3), 253–264. https://doi.org/10.1001/jama.297.3.253

Moscato, B. S., Russell, M., Zielezny, M., et al. (1997). Gender differences in the relation between depressive symptoms and alcohol problems: A longitudinal perspective. American Journal of Epidemiology, 146(11), 966–974. https://doi.org/10.1093/oxfordjournals.aje.a009224

Nam, E., Matejkowski, J., & Lee, S. (2017). Racial/ethnic differences in contemporaneous use of mental health and substance use treatment among individuals experiencing both mental illness and substance use disorders. Psychiatric Quarterly, 88(1), 185–198. https://doi.org/10.1007/s11126-016-9444-0

Nunes, E. V., & Levin, F. R. (2004). Treatment of depression in patients with alcohol or other drug dependence: A meta-analysis. JAMA, 291(15), 1887–1896. https://doi.org/10.1001/jama.291.15.1887

Nunes, E. V., Liu, X., Samet, S., et al. (2006). Independent versus substance-induced major depressive disorder in substance-dependent patients: Observational study of course during follow-up. Journal of Clinical Psychiatry, 67(10), 1561–1567. https://doi.org/10.4088/jcp.v67n1010

Nunes, E. V., Quitkin, F. M., Donovan, S. J., et al. (1998). Imipramine treatment of opiate-dependent patients with depressive disorders: A placebo-controlled trial.

Archives of General Psychiatry, 55(2), 153–160. https://doi.org/10.1001/archpsyc.55.2.153

Pedrelli, P., Shapero, B., Archibald, A., et al. (2016). Alcohol use and depression during adolescence and young adulthood: A summary and interpretation of mixed findings. Current Addiction Reports, 3(1), 91–97. https://doi.org/10.1007/s40429-016-0084-0

Petrakis, I., Ralevski, E., Nich, C., et al. (2007). Naltrexone and disulfiram in patients with alcohol dependence and current depression. Journal of Clinical Psychopharmacology, 27(2), 160–165. https://doi.org/10.1097/jcp.0b13e3180337fcb

Pettinati, H. M., Oslin, D. W., Kampman, K. M., et al. (2010). A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. The American Journal of Psychiatry, 167(6), 668–675. https://doi.org/10.1176/appi.ajp.2009.08060852

Prescott, C. A., Aggen, S. H., & Kendler, K. S. (2000). Sex-specific genetic influences on the comorbidity of alcoholism and major depression in a population-based sample of U.S. twins. Archives of General Psychiatry, 57(8), 803–811. https://doi.org/10.1001/archpsyc.57.8.803

Renoir, T., Pang, T. Y., & Lanfumey, L. (2012). Drug withdrawal-induced depression: Serotonergic and plasticity changes in animal models. Neuroscience & Biobehavioral Reviews, 36(1), 696–726. https://doi.org/10.1016/j.neubiorev.2011.10.003

Riper, H., Andersson, G., Hunter, S. B., et al. (2014). Treatment of comorbid alcohol use disorders and depression with cognitive-behavioural therapy and motivational interviewing: A meta-analysis. Addiction, 109(3), 394–406. https://doi.org/10.1111/add.12441

Salloum, I. M., Cornelius, J. R., Thase, M. E., et al. (1998). Naltrexone utility in depressed alcoholics. Psychopharmacology Bulletin, 34(1), 111–115.

Samet, S., Fenton, M. C., Nunes, E., et al. (2013). Effects of independent and substance-induced major depressive disorder on remission and relapse of alcohol, cocaine, and heroin dependence. Addiction, 108(1), 115–123. https://doi.org/10.1111/j.1360-0443.2012.04010.x

Schuckit, M. A., Tipp, J. E., Bergman, M., et al. (1997). Comparison of induced and independent major depressive disorders in 2,945 alcoholics. American Journal of Psychiatry, 154(7), 948–957. https://doi.org/10.1176/ajp.154.7.948

Smith, S. M., Stinson, F. S., Dawson, D. A., et al. (2006). Race/ethnic differences in the prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychological Medicine, 36(7), 987–998. https://doi.org/10.1017/S0033291706007690

Sullivan, L. E., Fiellin, D. A., & O'Connor, P. G. (2005). The prevalence and impact of alcohol problems in major depression: A systematic review. The American Journal of Medicine, 118(4), 330–341. https://doi.org/10.1016/j.amjmed.2005.01.007

Torrens, M., Fonseca, F., Mateu, G., et al. (2005). Efficacy of antidepressants in substance use disorders with and without comorbid depression: A systematic review and meta-analysis. Drug and Alcohol Dependence, 78(1), 1–22. https://doi.org/10.1016/j.drugalcdep.2004.09.004

Webb, C. A., Dillon, D. G., Pechtel, P., et al. (2016). Neural correlates of three promising endophenotypes of depression: Evidence from the EMBARC study. Neuropsychopharmacology, 41(2), 454–463. https://doi.org/10.1038/npp.2015.165

Wilcox, C. E., & Tonigan, J. S. (2018). Changes in depression mediate the effects of AA attendance on alcohol use outcomes. The American Journal of Drug and Alcohol Abuse, 44(1), 45–50. https://doi.org/10.1080/00952990.2017.1346981

Witte, J., Bentley, K., Evins, A. E., et al. (2012). A randomized, controlled, pilot study of acamprosate added to escitalopram in adults with major depressive disorder and alcohol use disorder. Journal of Clinical Psychopharmacology, 32(6), 787–796. https://doi.org/10.1097/JCP.0b013e3182726764

Zhou, H., Polimanti, R., Yang, B. Z., et al. (2017). Genetic risk variants associated with comorbid alcohol dependence and major depression. JAMA Psychiatry, 74(12), 1234–1241. https://doi.org/10.1001/jamapsychiatry.2017.3275